{"id":21064,"date":"2025-01-09T19:41:14","date_gmt":"2025-01-09T11:41:14","guid":{"rendered":"https:\/\/flcube.com\/?p=21064"},"modified":"2025-01-09T19:41:16","modified_gmt":"2025-01-09T11:41:16","slug":"xtalpis-ailux-biologics-partners-with-ucb-for-ai-driven-drug-discovery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21064","title":{"rendered":"Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery"},"content":{"rendered":"\n

Shenzhen-based QuantumPharm Inc. (HKG: 2228<\/a>), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB<\/a>), granting the Belgian biopharma commercial rights to utilize Ailux\u2019s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were disclosed.<\/p>\n\n\n\n

Ailux Biologics and AI Platforms<\/strong>
Ailux Bio, the macromolecular drug discovery unit of Xtalpi, is equipped with a proprietary database, AtlAX, and three major AI platforms. These include the structural modeling platform XtalFold, the generative protein big language model XenProT, and the macromolecular drug property prediction platform Xentient. These platforms are designed to accelerate the discovery and development of innovative macromolecular drugs.<\/p>\n\n\n\n

Significance of the Partnership<\/strong>
This partnership between Ailux Biologics and UCB highlights the growing importance of AI in drug discovery and development. By leveraging Ailux\u2019s advanced AI platforms, UCB aims to enhance its capabilities in discovering and engineering macromolecular drugs, potentially leading to more effective treatments for various diseases.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary…<\/p>\n","protected":false},"author":1,"featured_media":21065,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,2325,2015,1112,695,131,696],"class_list":["post-21064","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-ailux-biologics","tag-ebr-ucb","tag-hkg-2228","tag-quantumpharm","tag-ucb","tag-xtalpi"],"yoast_head":"\nXtalpi's Ailux Biologics Partners with UCB for AI-Driven Drug Discovery - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux\u2019s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21064\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xtalpi's Ailux Biologics Partners with UCB for AI-Driven Drug Discovery\" \/>\n<meta property=\"og:description\" content=\"Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux\u2019s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were disclosed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21064\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T11:41:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T11:41:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0903.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"462\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery\",\"datePublished\":\"2025-01-09T11:41:14+00:00\",\"dateModified\":\"2025-01-09T11:41:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064\"},\"wordCount\":178,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0903.png\",\"keywords\":[\"AI\",\"Ailux Biologics\",\"EBR: UCB\",\"HKG: 2228\",\"QuantumPharm\",\"UCB\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21064#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21064\",\"name\":\"Xtalpi's Ailux Biologics Partners with UCB for AI-Driven Drug Discovery - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0903.png\",\"datePublished\":\"2025-01-09T11:41:14+00:00\",\"dateModified\":\"2025-01-09T11:41:16+00:00\",\"description\":\"Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux\u2019s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21064\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0903.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0903.png\",\"width\":1080,\"height\":462,\"caption\":\"Xtalpi's Ailux Biologics Partners with UCB for AI-Driven Drug Discovery\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21064#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xtalpi's Ailux Biologics Partners with UCB for AI-Driven Drug Discovery - Insight, China's Pharmaceutical Industry","description":"Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux\u2019s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21064","og_locale":"en_US","og_type":"article","og_title":"Xtalpi's Ailux Biologics Partners with UCB for AI-Driven Drug Discovery","og_description":"Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux\u2019s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were disclosed.","og_url":"https:\/\/flcube.com\/?p=21064","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-09T11:41:14+00:00","article_modified_time":"2025-01-09T11:41:16+00:00","og_image":[{"width":1080,"height":462,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0903.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21064#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21064"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery","datePublished":"2025-01-09T11:41:14+00:00","dateModified":"2025-01-09T11:41:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21064"},"wordCount":178,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21064#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0903.png","keywords":["AI","Ailux Biologics","EBR: UCB","HKG: 2228","QuantumPharm","UCB","Xtalpi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21064#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21064","url":"https:\/\/flcube.com\/?p=21064","name":"Xtalpi's Ailux Biologics Partners with UCB for AI-Driven Drug Discovery - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21064#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21064#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0903.png","datePublished":"2025-01-09T11:41:14+00:00","dateModified":"2025-01-09T11:41:16+00:00","description":"Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux\u2019s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21064#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21064"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21064#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0903.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0903.png","width":1080,"height":462,"caption":"Xtalpi's Ailux Biologics Partners with UCB for AI-Driven Drug Discovery"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21064#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0903.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21064"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21064\/revisions"}],"predecessor-version":[{"id":21066,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21064\/revisions\/21066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21065"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}